Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma [Gynecologic Cancer]

Conclusion Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. Inhibition of the PI3K/Akt/mTOR pathway may be a viable therapeutic target.

http://jco.ascopubs.org/cgi/content/short/33/31/3576?rss=1

Source: Journal of Clinical Oncology - October 29, 2015 Category: Cancer & Oncology Authors: Oza, Pignata, Poveda, McCormack, Clamp, Schwartz, Cheng, Li, Campbell, Dodion, Haluska Tags: Chemotherapy, Combined Modality, Translational Oncology Gynecologic Cancer Source Type: research